Search Results - "Caramazza, D"

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons by Tefferi, A, Lasho, T L, Finke, C M, Knudson, R A, Ketterling, R, Hanson, C H, Maffioli, M, Caramazza, D, Passamonti, F, Pardanani, A

“…Calreticulin ( CALR ) mutations were recently described in JAK2 and MPL unmutated primary myelofibrosis (PMF) and essential thrombocythemia. In the current…”
Get full text

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis by Passamonti, F, Giorgino, T, Mora, B, Guglielmelli, P, Rumi, E, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R T, Benevolo, G, Albano, F, Caramazza, D, Merli, M, Pietra, D, Casalone, R, Rotunno, G, Barbui, T, Cazzola, M, Vannucchi, A M

“…Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with variable risk of evolution into post-PV and post-ET…”
Get full text

Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients by Passamonti, F, Mora, B, Giorgino, T, Guglielmelli, P, Cazzola, M, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R, Benevolo, G, Albano, F, Caramazza, D, Rumi, E, Merli, M, Pietra, D, Casalone, R, Barbui, T, Pieri, L, Vannucchi, A M

Get full text

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis by Tefferi, A, Lasho, T L, Abdel-Wahab, O, Guglielmelli, P, Patel, J, Caramazza, D, Pieri, L, Finke, C M, Kilpivaara, O, Wadleigh, M, Mai, M, McClure, R F, Gilliland, D G, Levine, R L, Pardanani, A, Vannucchi, A M

“…In a multi-institutional collaborative project, 1473 patients with myeloproliferative neoplasms (MPN) were screened for isocitrate dehydrogenase 1 ( IDH1 )/…”
Get full text

Robotic sacrocolpopexy plus ventral rectopexy as combined treatment for multicompartment pelvic organ prolapse using the new Hugo RAS system by Campagna, G., Panico, G., Vacca, L., Caramazza, D., Mastrovito, S., Lombisani, A., Ercoli, A., Scambia, G.

Get full text

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients by Caramazza, D, Begna, K H, Gangat, N, Vaidya, R, Siragusa, S, Van Dyke, D L, Hanson, C, Pardanani, A, Tefferi, A

“…We have previously identified sole +9, 13q- or 20q-, as ‘favorable’ and sole +8 or complex karyotype as ‘unfavorable’ cytogenetic abnormalities in primary…”
Get full text

Intravesical misplacement of vaginal contraceptive ring: a video report and review of the literature by Panico, G, Campagna, G, Mastrovito, S, Arrigo, D, Caramazza, D, Scambia, G, Ercoli, A

“…The NuvaRing®, a hormonal vaginal contraceptive device, has gained widespread usage due to its favourable efficacy and safety profiles. Exceedingly rare…”
Get full text

Laparoscopic sacrocolpopexy plus ventral rectopexy as combined treatment for multicompartment pelvic organ prolapse by Campagna, G., Panico, G., Caramazza, D., Anchora, L. P., Parello, A., Gallucci, V., Vacca, L., Scambia, G., Ercoli, A., Ratto, C.

“…Background Pelvic organ prolapse (POP) is a dynamic disorder that affects the entire pelvic diaphragm. POP may often involve multiple organs. Abdominal…”
Get full text

WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations by Patnaik, M M, Lasho, T L, Finke, C M, Gangat, N, Caramazza, D, Holtan, S G, Pardanani, A, Knudson, R A, Ketterling, R P, Chen, D, Hoyer, J D, Hanson, C A, Tefferi, A

“…The 2008 World Health Organization (WHO) criteria were used to identify 88 consecutive Mayo Clinic patients with ‘myelodysplastic syndrome with isolated…”
Get full text

Laparoscopic sacral hysteropexy for pelvic organ prolapse in a patient affected by marfan syndrome: a case report by Campagna, G, Vacca, L, Caramazza, D, Panico, G, Mastrovito, S, Scambia, G, Ercoli, A

“…Marfan Syndrome (MS) is a dominantly inherited connective tissue disorder with consequences on the strength and resilience of connective tissues that may…”
Get full text

Looking for CALR mutations in familial myeloproliferative neoplasms by Maffioli, M, Genoni, A, Caramazza, D, Mora, B, Bussini, A, Merli, M, Giorgino, T, Casalone, R, Passamonti, F

Get full text

Laparoscopic sacrocolpopexy plus ventral rectopexy for multicompartment pelvic organ prolapse by Campagna, G., Panico, G., Caramazza, D., Gallucci, V., Pizzacalla, S., Ercoli, A., Scambia, G., Parello, A., Ratto, C.

Get full text

Leukemia risk models in primary myelofibrosis: an International Working Group study by Tefferi, A, Pardanani, A, Gangat, N, Begna, K H, Hanson, C A, Van Dyke, D L, Caramazza, D, Vannucchi, A M, Morra, E, Cazzola, M, Pereira, A, Cervantes, F, Passamonti, F

Get full text

IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia by Caramazza, D, Lasho, T L, Finke, C M, Gangat, N, Dingli, D, Knudson, R A, Siragusa, S, Hanson, C A, Pardanani, A, Ketterling, R P, Tefferi, A

Get full text

Patients requiring interruption of long‐term oral anticoagulant therapy: the use of fixed sub‐therapeutic doses of low‐molecular‐weight heparin by MALATO, A., SACCULLO, G., LO COCO, L., CARAMAZZA, D., ABBENE, I., PIZZO, G., CASUCCIO, A., SIRAGUSA, S.

“…Introduction: We tested the efficacy and safety of fixed doses of low‐molecular‐weight heparin (LMWH) in patients requiring interruption of vitamin‐K…”
Get full text

500 EFFECTS OF COVID-19 PANDEMICS ON SYMPTOMS AND QUALITY OF LIFE IN PATIENTS AFFECTED BY INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME (IC/PBS) AND IRRITABLE BOWEL SYNDROME (IBS) by Marturano, M, Campagna, G, Gaetani, E, Natale, F, Mastrovito, S, Vacca, L, Panico, G, Caramazza, D, Troisi, P, Lombisani, A, Scambia, G, Ercoli, A

Get full text

MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms by Patnaik, M M, Lasho, T L, Finke, C M, Gangat, N, Caramazza, D, Siragusa, S, Hanson, C A, Pardanani, A, Tefferi, A

Get full text

Trisomy 11: prevalence among 22 403 unique patient cytogenetic studies and clinical correlates by Caramazza, D, Ketterling, R P, Knudson, R A, Hanson, C A, Siragusa, S, Pardanani, A, Tefferi, A

Get full text

Gastrointestinal bleeding due to angiodysplasia in patients with type 1 von Willebrand disease: report on association and management by SIRAGUSA, S., MALATO, A., COCO, L. LO, CIGNA, V., SACCULLO, G., ABBENE, I., ANASTASIO, R., CARAMAZZA, D., PATTI, R., ARCARA, M., VITA, G. DI

Get full text

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study by TEFFERI, Ayalew, VAIDYA, Rakhee, CARAMAZZA, Domenica, FINKE, Christy, LASHO, Terra, PARDANANI, Animesh

“…Abnormal cytokine expression accompanies myelofibrosis and might be a therapeutic target for Janus-associated kinase (JAK) inhibitor drugs. This study…”
Get full text